# 該藥物為阿茲海默症相關躁動症患者提供新的治療選擇。

*biotech · news · 2026-05-01 · Newsmax*

## Key points

- FDA 已核准 Axsome Therapeutics 的 Auvelity 用於治療阿茲海默症患者的躁動症。
- Auvelity 提供抗精神病藥物的替代方案，後者對這些患者存在嚴重安全風險。
- 多達 70% 的美國阿茲海默症患者會出現躁動症，過去缺乏較安全的治療選擇。
- Auvelity 是首款獲 FDA 核准專門針對阿茲海默症相關躁動症的藥物。

The U.S. Food and Drug Administration has approved Axsome Therapeutics' drug to treat agitation in patients ‌with Alzheimer's ​disease, the company said on Friday. The drug, branded ⁠as Auvelity, offers ​a new treatment option for patients ⁠with Alzheimer's-related agitation, marked by restlessness, aggression and emotional distress. ‌These patients have long ​relied on ‌antipsychotic drugs, which had ‌serious safety risks. Alzheimer's disease, the most common form of dementia, affects ⁠about 7 ‌million people ⁠in the United States. ⁠Agitation occurs ⁠in up to 70% of ‌the patients, contributing to faster cognitive decline, heavier burden on ‌caregivers, ​and ‌higher risk of death.

**Companies:** Axsome Therapeutics
**Countries:** United States

[Read the full story on Newsmax](https://www.newsmax.com/health/health-news/alzheimers-medication-agitation/2026/05/01/id/1254876/)

---

Canonical: https://newsio.io/zh-TW/n/3fd9213b-3765-4657-aca2-a498207def2f/700
Summarized by Newsio from Newsmax. https://newsio.io/how-it-works